Skip Nav Destination
Antiviral cell therapy: is this the future?
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
Issue Archive
June 27 2013
In this Issue
Table of Contents
INSIDE BLOOD
CLINICAL TRIALS AND OBSERVATIONS
Antiviral cell therapy: is this the future?
Clinical Trials & Observations
BLOOD WORK
PLENARY PAPER
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen,Catherine M. Bollard,Adam M. Mendizabal,Elizabeth J. Shpall,Paul Szabolcs,Joseph H. Antin,Neena Kapoor,Sung-Yun Pai,Scott D. Rowley,Partow Kebriaei,Bimalangshu R. Dey,Bambi J. Grilley,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop
BLOOD SPOTLIGHT
REVIEW SERIES
CLINICAL TRIALS AND OBSERVATIONS
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia
Clinical Trials & Observations
Domenico Russo,Giovanni Martinelli,Michele Malagola,Cristina Skert,Simona Soverini,Ilaria Iacobucci,Antonio De Vivo,Nicoletta Testoni,Fausto Castagnetti,Gabriele Gugliotta,Diamante Turri,Michela Bergamaschi,Patrizia Pregno,Ester Pungolino,Fabio Stagno,Massimo Breccia,Bruno Martino,Tamara Intermesoli,Carmen Fava,Elisabetta Abruzzese,Mario Tiribelli,Catia Bigazzi,Bruno Mario Cesana,Gianantonio Rosti,Michele Baccarani
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia
Clinical Trials & Observations
Susanne Radtke,Oliver Zolk,Bertold Renner,Marios Paulides,Martin Zimmermann,Anja Möricke,Martin Stanulla,Martin Schrappe,Thorsten Langer
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
Brief Report
David T. Teachey,Susan R. Rheingold,Shannon L. Maude,Gerhard Zugmaier,David M. Barrett,Alix E. Seif,Kim E. Nichols,Erica K. Suppa,Michael Kalos,Robert A. Berg,Julie C. Fitzgerald,Richard Aplenc,Lia Gore,Stephan A. Grupp
HEMATOPOIESIS AND STEM CELLS
HIF prolyl hydroxylase 2 (PHD2) is a critical regulator of hematopoietic stem cell maintenance during steady-state and stress
Rashim Pal Singh,Kristin Franke,Joanna Kalucka,Soulafa Mamlouk,Antje Muschter,Agnieszka Gembarska,Tatyana Grinenko,Carsten Willam,Ronald Naumann,Konstantinos Anastassiadis,A. Francis Stewart,Stefan Bornstein,Triantafyllos Chavakis,Georg Breier,Claudia Waskow,Ben Wielockx
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels
Natalia Rydz,Laura L. Swystun,Colleen Notley,Andrew D. Paterson,J. Jacob Riches,Kate Sponagle,Boonchai Boonyawat,Robert R. Montgomery,Paula D. James,David Lillicrap
TRANSPLANTATION
CORRESPONDENCE
ERRATA
-
Cover Image
Cover Image
![issue cover]()
To verify that VWF binding colocalized with CLEC4M expression on the cell surface, CLEC4M-expressing cells were incubated with Humate-P (2 U/mL VWF) for 30 minutes, fixed, and labeled for CLEC4M (red), VWF (green), and DAPI (blue). Colocalization of VWF with CLEC4M is observed in yellow (merge). See the article by Rydz et al on page 5228.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
